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Limits to the Use
of the Procalcitonin Level
as a Diagnostic Marker
Sir—The comparison by Simon et al. [1]
of the accuracy of serum C-reactive pro-
tein levels and procalcitonin levels for the
diagnosis of bacterial infections is most
interesting. Three important points, how-
ever, merit comment.
First, with regard to the source of pro-
calcitonin, recent findings have revealed
that, in marked inflammation, and espe-
cially in systemic infection [2], the calci-
tonin (CT) gene is ubiquitously expressed
in parenchymal cells. Thus, the expression
of the CT gene is not limited to liver or
leukocyte cells. Furthermore, in leuko-
cytes, CT gene expression is only very
limited and transient [3]. No CT gene ex-
pression is found if these cells are har-
vested from patients who have sepsis and
markedly elevated serum procalcitonin
levels. In whole blood, lipopolysaccharide
stimulation is unable to induce any de-
tectable procalcitonin production by leu-
kocytes. Moreover, the observation that
some patients with sepsis have high serum
procalcitonin levels even after near-com-
plete eradication of their leukocyte pop-
ulation by chemotherapy suggests that
these cells are not a major source of pro-
calcitonin. Parenchymal cells (including
liver, kidney, and muscle cells and adi-
pocytes) constitute the largest mass of tis-
sue and the principal source of circulating
procalcitonin in patients with sepsis [4].
Procalcitonin, a prototype of hormokine
mediators, can follow either a classical
hormonal expression pathway or, alter-
natively, a cytokine-like expression path-
way. The ubiquitous production of this
hormokine is triggered by microbial
toxins (e.g., lipopolysaccharides) together
with mediators from humoral or cell-me-
diated host responses (e.g. IL-1b and TNF-
a). These findings are relevant, as they are
the basis for the superior diagnostic ac-
curacy of procalcitonin levels, compared
with C-reactive protein levels, as is shown
in the excellent meta-analysis of Simon et
al. [1].
Second, for the appropriate use of a
marker in a clinical setting, the functional
assay sensitivity is more relevant than
the reported detection limit. The com-
mercially available 2-site assay (LUMItest
PCT; distributed by Brahms) used by
Simon et al. [1] is useful to detect mark-
edly elevated procalcitonin levels in pa-
tients with severe systemic bacterial infec-
tion or sepsis. However, this assay has the
disadvantage of relative insensitivity, with
a functional detection limit of 0.5 ng/mL
procalcitonin. On the basis of measure-
ments made with an ultrasensitive re-
search assay, a study found that 30 healthy
donors had a mean procalcitonin level
(SD) of ng/mL [5]. Thus,0.03 0.02
the LUMItest assay is not sensitive enough
to detect mildly or moderately elevated
procalcitonin levels, which limits its di-
agnostic use in conditions other than overt
sepsis. For research purposes, more-
sensitive procalcitonin assays have been
described [5].
Last, any observational study investi-
gating the diagnostic accuracy of a given
marker is biased by the choice of the “gold
standard.” As Simon et al. [1] correctly
state, this standard does not exist with re-
spect to infection, and thus all studies are
prone to potential bias. Importantly, in-
terventional studies in which the antimi-
crobial therapy is guided by the marker
and the “gold standard” for diagnosis is
the outcome have the potential to resolve
this dilemma. With respect to procalci-
tonin levels, initial studies of lower respi-
ratory-tract infections and meningitis
have shown promising results [6, 7]. The
time has arrived for investigators to con-
duct more intervention studies for other
sites of infection, using more-sensitive
procalcitonin assays to tackle the vicious
cycle of antibiotic overuse and emerging
multidrug resistance.
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